gw786034

Wilms Tumor

National Cancer Institute (NCI)Phase 1Dormant

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 89/ 100

Competitive context

40 Active assets in the Wilms Tumor cohort.

Asset / Sponsor	Phase	Rating
(+)-VINCRISTINE Centre Oscar Lambret	Phase 2	BB
Inno-206 Children's National Research Institute	Phase 2	BB
Itraconazole Samsung Medical Center	Phase 4	BB
Irinotecan Centre Oscar Lambret	Phase 2	BB
Cyclophosphamide St. Jude Children's Research Hospital	Phase 2	BB

View all 50 →

Same molecule, other indications

gw786034 is also rated in:

renal cell carcinomaDormant

BBB

Indicative ·

79 / 100

nonpapillary renal cell carcinomaDormant

BBB

Indicative ·

73 / 100

ovarian neoplasmDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.